Novel drug delivery approaches to bypass P- glycoprotein efflux pump

Pharmaceutical Reviews

Volumn 9, Issue 1, 2011, Pages

  Gohel, Mukesh C ^a   Parikh, Rajesh K ^a   Modi, Sanjay C ^a   Vyas, Kalpesh G ^a   Sheth, Krushit M ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

ABCB1; MDR1; MRP; P gp efflux pump; P gp inhibitors; P gp substrates

Indexed keywords

ANTIARRHYTHMIC AGENT; BIRICODAR; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DENDRIMER; DIGOXIN; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LANIQUIDAR; LIPOSOME; MACROGOL; MACROGOL STEARATE; METHOTREXATE; NANOCARRIER; PACLITAXEL; POLOXAMER; POLYMER; POLYSORBATE; RITONAVIR; TARIQUIDAR; THIOMER DERIVATIVE; TOCOFERSOLAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZIDOVUDINE; ZOSUQUIDAR;

BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL MEMBRANE TRANSPORT; CELLULAR DISTRIBUTION; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOSOMAL DELIVERY; LIVER TOXICITY; MEMBRANE MODEL; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

EID: 79955737808     PISSN: None     EISSN: 19185561     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I., Gottesman, M.M., Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398, 1999.
2. Germann, U.A., P-glycoprotein: a mediator of multidrug resistance in tumor cells. Eur. J. Cancer 32A, 927-944, 1996.
3. Schinkel, A.H., The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8, 161-170, 1997.
4. Romiti, N., Tramonti, G., Donati, A., Chieli, E., Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci. 76, 293-302, 2004.
5. Stouch, T.R., Gudmundsson, O., Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev.54, 315-328, 2002.
6. Smit, J. J., Schinkel, A. H., Oude-Elferink, R. P., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A., Ottenhoff, R., van der Lugt, N. M., van Roon, M. A., Offerhaus, G. J. A., Berns, A. J. M., and Borst, P. Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 75: 451-62, 1993.
7. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., and Borst, P. Absence of the MDR1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest, 96: 1698-705, 1995.
8. Barrand, M. A., Robertson, K. J., and von Weikersthal, S. F. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett, 374: 179-83, 1995.
9. Lum, B. L., and Gosland, M. P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am, 9: 319-36, 1995.
10. Higgings CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci; 17:18-21, 1992.
11. Rosenberg MF, Kamis AB, Collaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003 (in press).
12. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem; 62: 385-427, 1993.
13. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr; 33:481-91, 2001.
14. Edwards Filaria Journal 2(Suppl 1):S8 doi: 10.1186/1475-2883-2-S1-S8, 2003.
15. Kartner, N., Riordan, J.R., Ling, V., Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288, 1983.
16. Osherovich, Beating the brain's bouncer, L. sciBX 2 (19);10.1038/sciBX.,773, 2009.
17. Thomas, H. and Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159-165, 2003.
18. Krishna, R. and Mayer, L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283, 2000.
19. Ferry, D.R., Traunecker, H. and Kerr, D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer. A 32, 1070-1081, 1996.
20. Gottesman, M.M., Fojo, T. and Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2, 48-58, 2002.
21. Fischer, V., Rodriguez-Gascon, A., Heitz, F., Tynes, R., Hauck, C., Cohen, D. and Vickers, A.E. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26, 802-811, 1998.
22. J. Jodoin, M. Demeule, and R. Beliveau. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta 1542:149-159, 2002.
23. Y. Honda, F. Ushigome, N. Koyabu, S. Morimoto, Y. Shoyama, T. Uchiumi, M. Kuwano, H. Ohtani, and Y. Sawada. Effects of grapefruit juice and orange juice components on P-glycoprotein-and MRP2-mediated drug efflux. Br. J. Pharmacol. 143:856-864, 2004.
24. B. Carreno-Gomez and R. Duncan. Compositions with enhanced oral bioavailability. USP 20030211072, 2002.
25. B. M. Johnson, W. N. Charman, and C. J. H. Porter. An in vitro examination of the impact of polyehtylene glycol 400, pluronic P 85 and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 4(4), 2002.
26. Q. Shen, Y. Lin, T. Handa, M. Doi, M. Sugie, K. Wakayama, N. Okada, T. Fujita, and A. Yamamoto. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 313:49-56, 2006.
27. E. D. Hugger, K. L. Audus, and R. T. Borchardt., Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 91:1980-1990, 2002.
28. E. D. Hugger, B. L. Novak, P. S. Burton, K. L. Audus, and R. T. Borchardt. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J. Pharm. Sci. 91:1991-2002, 2002.
29. E. M. Collnot, C. Baldes, M. F. Wempe, J. Hyatt, L. Navarro, K. J. Edgar, U. F. Schaefer, and C.M. Lehr. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Release 111:35-40, 2006.
30. E. Friche, P. B. Jensen, M. Sehested, E. J. Demant, and N. N. Nissen., The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 2:297-303, 1990.
31. Y. Shono, H. Nishihara, Y. Matsuda, S. Furukawa, N. Okada, T. Fujita, and A. Yamamoto., Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93:877-885, 2004.
32. Y. L. Lo. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 90:37-48, 2003.
33. H. Zhang, M. Yao, R. A. Morrison, and S. Chong. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch. Pharm. Res. 26:768-772, 2003.
34. B. D. Rege, J. P. Kao, and J. E. Polli. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16:237-246, 2002.
35. R. L. Hunter, J. McNicholl, and A. A. Lal. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retrovir. 10:95-98, 1994.
36. G. Rodeheaver, V. Turnbull, M. T. Edgerton, L. Kurtz, and R. F. Edlich. Pharmacokinetics of a new skin wound cleanser. Am. J. Surg. 132:67-74, 1976.
37. E. V. Batrakova, S. Li, S. V. Vinogradov, V. Alakhov, D. W. Miller, and A. V. Kabanov. Mechanism of pluronic effect on P-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. Pharmacol. Exp. Ther. 299:483-493, 2001.
38. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54:759-779, 2002.
39. V. Alakhov, E. Klinksi, S. Li, G. Pietrzynski, A. Venne, E. Batrakova, T. Bronitch, and A. V. Kabanov., Block co-polymer based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf., B Biointerfaces 16:113-134, 1999.
40. A. Venne, S. Li, A. Mandeville, A. V. Kabanov, and V. Alakhov., Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56(16):3626-3629, 1996.
41. E. Batrakova, S. Lee, S. Li, A. Venne, V. Alakhov, and A. V. Kabanov., Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1373-1379, 1999.
42. E. V. Batrakova, S. Li, Y. Li, V. Y. Alakhov, and A. V. Kabanov. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 21:2226-2233, 2004.
43. A. Bernkop-Schnurch. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57:1569-1582, 2004.
44. M. Werle and M. Hoffer. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release 111:41-46, 2006.
45. H. L. Luessen, C. O. Rentel, A. F. Kotze, C.M. Lehr, A. B. G. de Boer, J. C. Verhoef, and H. E. Junginger. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release 45(1):15-23, 1997.
46. L. Bromberg., Interactions among proteins and hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. 53:541-547, 2001.
47. H. L. Luessen, C.-M. Lehr, C.-O. Rentel, A. B. J. Noach, A. G. de Boer, J. C. Verhoef, and H. E. Junginger., Bioadhesive polymers for the peroral delivery of peptide drugs. J. Control. Release 29:329-338, 1994.
48. A. Bernkop-Schnurch and V. Grabovac., Polymeric efflux pump inhibitors in oral drug delivery. Am. J. Drug Deliv. 4:263-272, 2006.
49. Matsuo, H., Wakasugi, M., Takanaga, H., Ohtani, H., Naito, M., Tsuruo, T., Sawada, Y., Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J. Control. Release 77, 77-86, 2001.
50. Oudard, S., Thierry, A., Jorgensen, T.J., Rahman, A., Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol. 28, 259-265, 1991.
51. Thierry, A.R., Vige, D., Coughlin, S.S., Belli, J.A., Dritschilo, A., Rahman, A., Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7, 572-579, 1993.
52. Poste, G., Papahadjopoulos, D., Drug-containing lipid vesicles render drug-resistant cell sensitive to actinomycin D. Nature 261, 699-701, 1976.
53. Fan, D., Bucana, C.D., O'Brian, C.A., Zwelling, L.A., Seid, C., Fidler, I.J., Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res. 50, 3619-3626, 1990.
54. Lee, K.D., Hong, K., Papahadjopoulos, D., Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim. Biophys. Acta 1103, 185-197, 1992.
55. Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691-743, 1999.
56. Van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P., van Meer, G., MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87, 507-517, 1996.
57. Bosch, I., Dunussi-Joannopoulos, K., Wu, R.L., Furlong, S.T., Croop, J., Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36, 5685-5694, 1997.
58. Romsicki, Y., Sharom, F.J., The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38, 6887-6896, 1999.
59. Lo, Y.L., Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 60, 1381-1390, 2000.
60. Advani, R., Fisher, G.A., Lum, B.L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B.I., A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin. Cancer Res. 7, 1221-1229, 2001.
61. Kang, M.H., Figg, W.D., Ando, Y., Blagosklonny, M.V., Liewehr, D., Fojo, T., Bates, S.E., The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin. Cancer Res. 7, 1610-1617, 2001.
62. Krishna, R., Mayer, L.D., Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 57, 5246-5253, 1997.
63. Krishna, R., McIntosh, N., Riggs, K.W., Mayer, L.D., Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit non-encapsulated drug excretion. Clin. Cancer Res. 5, 2939-2947, 1999.
64. Daoud, S.S., Juliano, R.L., Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes. Cancer Res. 46, 5518-5523, 1986.
65. Daoud, S.S., Juliano, R.L., Modulation of doxorubicin resistance by valinomycin (NSC 122023) and liposomal valinomycin in Chinese hamster ovary cells. Cancer Res. 49, 2661-2667, 1989.
66. Koukourakis, M.I., Koukouraki, S., Fezoulidis, I., et al., High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83, 1281-1286, 2000.
67. Mohrbacher, A.F., Gregory, S.A., Gabriel, D.A., Rusk, J.M., Giles, F.J., Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer 94, 2645-2652, 2002.
68. Batist, G., Barton, J., Chaikin, P., Swenson, C., Welles, L., Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin. Pharmacother. 12, 1739-1751, 2002.
69. Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K., van Asperen, J., Borst, P., and Schinkel, A. H., Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the MDR1a P-glycoprotein. Br J Pharmacol, 119: 1038-44, 1996.
70. Benet L., The drug efflux metabolism alliance: Biochemical Aspects. Adv Drug delivery review: 50: S3-S11, 2001.
71. Dintaman J M. Silverman J A, Inhibition of P-glycoprotein by D-α-tocopheryl polyethelene glycol 1000 succinate (TPGS). Pharm Res; 16: 1550-6, 1999.